Matthew Moisan
Overview
Matthew Moisan is a co-lead of the Emerging Companies and Venture Capital practice and a resident in the firm's New York City office. He represents ECVC clients in structuring, formation, growth, and exits while providing practical, effective, business-minded counsel based on a keen awareness of the entrepreneurial lifecycle. Matthew has a unique way of deciphering his clients’ goals and an ability to turn complex legal issues into actionable business items. While his representation often begins when a company is merely an idea on the back of a napkin, he is also frequently engaged when the stakes are the highest: negotiating the sale of the business.
Career & Education
- Boston University, B.A., 2005
- Touro College Jacob D. Fuchsberg Law Center, J.D., 2008
- New York
Matthew's Insights
Client Alert | 6 min read | 07.22.25
The One Big Beautiful Bill Act Expands Favorable QSBS Treatment
On July 4, 2025, President Trump signed into law the One Big Beautiful Bill Act (the “Act”), after it was passed by Congress on July 3, 2025. Notably, the Act made significant and welcome changes from the perspective of startup company stockholders and venture capital investors to the qualified small business stock (“QSBS”) rules set forth in Internal Revenue Code (“Code”) Section 1202. In a nutshell, the changes modernize (by adjusting for inflation) and expand the already favorable tax treatment for QSBS under Code Section 1202. The Act also permanently reinstates elective expensing for qualifying domestic research and experimental expenditures that will likely help more startups in research and capital intensive sectors qualify for favorable QSBS treatment.
Publication | Summer 2025
Event | 05.21.25
Client Alert | 5 min read | 03.26.25
Insights
New York Smart Business Dealmakers Conference
|06.06.24
Crowell & Moring and The Ember Company Present: The FIRESIDE
|05.29.24
- |
02.11.22
The Wall Street Journal
Matthew's Insights
Client Alert | 6 min read | 07.22.25
The One Big Beautiful Bill Act Expands Favorable QSBS Treatment
On July 4, 2025, President Trump signed into law the One Big Beautiful Bill Act (the “Act”), after it was passed by Congress on July 3, 2025. Notably, the Act made significant and welcome changes from the perspective of startup company stockholders and venture capital investors to the qualified small business stock (“QSBS”) rules set forth in Internal Revenue Code (“Code”) Section 1202. In a nutshell, the changes modernize (by adjusting for inflation) and expand the already favorable tax treatment for QSBS under Code Section 1202. The Act also permanently reinstates elective expensing for qualifying domestic research and experimental expenditures that will likely help more startups in research and capital intensive sectors qualify for favorable QSBS treatment.
Publication | Summer 2025
Event | 05.21.25
Client Alert | 5 min read | 03.26.25
